Literature DB >> 19464009

The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process.

T Hugh Jones1, Farid Saad.   

Abstract

It is becoming increasingly evident that the low serum levels of testosterone experienced by aging men are associated with increased all-cause mortality from CHD and other vascular disorders. Achieving a normal physiological testosterone concentration through the administration of testosterone therapy has been shown to provide beneficial effects on the pathophysiological markers and clinical symptoms of CHD. Many of the factors involved in the atherosclerotic process are interlinked with other, increasingly prevalent pathological conditions such as obesity, the metabolic syndrome (MetS), type 2 diabetes and erectile dysfunction, suggesting that testosterone therapy has potentially wide-ranging health benefits. As the number and scope of testosterone substitution and androgen deprivation studies increases and evidence accumulates, it is timely to assess available data and this review summarises the current understanding of the effects of testosterone on cardiovascular risk factors with particular emphasis on the relevance of testosterone treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464009     DOI: 10.1016/j.atherosclerosis.2009.04.016

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  36 in total

1.  Effect of treatment with testosterone on endothelial function in hypogonadal men: a systematic review and meta-analysis.

Authors:  Andrea Sansone; Giulia Rastrelli; Angelo Cignarelli; Maurizio de Rocco Ponce; Rosita Angela Condorelli; Elisa Giannetta; Elisa Maseroli; Sara Pinto; Ciro Salzano; Daniele Santi
Journal:  Int J Impot Res       Date:  2019-06-24       Impact factor: 2.896

2.  An update on male hypogonadism therapy.

Authors:  Prasanth Surampudi; Ronald S Swerdloff; Christina Wang
Journal:  Expert Opin Pharmacother       Date:  2014-04-23       Impact factor: 3.889

Review 3.  Cross-sex hormone therapy for gender dysphoria.

Authors:  B Fabris; S Bernardi; C Trombetta
Journal:  J Endocrinol Invest       Date:  2014-11-18       Impact factor: 4.256

4.  The relationship between reduced testosterone, stimulated growth hormone secretion and increased carotid intima-media thickness in obese men.

Authors:  Hideo Makimura; Takara L Stanley; Noelle Sun; Jean M Connelly; Linda C Hemphill; Steven K Grinspoon
Journal:  Clin Endocrinol (Oxf)       Date:  2010-11       Impact factor: 3.478

Review 5.  Testosterone in men with hypogonadism and high cardiovascular risk, Pros.

Authors:  Giuseppe M C Rosano; Cristiana Vitale; Massimo Fini
Journal:  Endocrine       Date:  2015-03-07       Impact factor: 3.633

6.  Association of sex hormones, aging, and atrial fibrillation in men: the Framingham Heart Study.

Authors:  Jared W Magnani; Carlee B Moser; Joanne M Murabito; Lisa M Sullivan; Na Wang; Patrick T Ellinor; Ramachandran S Vasan; Emelia J Benjamin; Andrea D Coviello
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-03-08

7.  Testosterone and the metabolic syndrome.

Authors:  Vakkat Muraleedharan; T Hugh Jones
Journal:  Ther Adv Endocrinol Metab       Date:  2010-10       Impact factor: 3.565

8.  Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging?

Authors:  Ozkan Gungor; Fatih Kircelli; Juan Jesus Carrero; Gulay Asci; Huseyin Toz; Erhan Tatar; Ender Hur; Mehmet Sukru Sever; Turgay Arinsoy; Ercan Ok
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-22       Impact factor: 8.237

9.  The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2.

Authors:  Farid Saad; Louis J Gooren
Journal:  J Obes       Date:  2010-08-10

10.  Testosterone delays vascular smooth muscle cell senescence and inhibits collagen synthesis via the Gas6/Axl signaling pathway.

Authors:  Yan-qing Chen; Jing Zhao; Cheng-wei Jin; Yi-hui Li; Meng-xiong Tang; Zhi-hao Wang; Wei Zhang; Yun Zhang; Li Li; Ming Zhong
Journal:  Age (Dordr)       Date:  2016-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.